Prime Medicine, Inc. (PRME)
(Delayed Data from NSDQ)
$4.43 USD
+0.13 (2.91%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.42 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRME 4.43 +0.13(2.91%)
Will PRME be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PRME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRME
Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know
PRME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PRME
12 Health Care Stocks Moving In Friday's After-Market Session
Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlook
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
Buy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic Progress
Prime Medicine initiated with bullish view at Chardan, here's why